Cell Point

Why is Cell Point (India) Ltd falling/rising?

As of 02-Sep, Cell Point (India) Ltd's stock price is at 16.00, down 1.54%. The stock is underperforming against the Sensex and has shown negative long-term performance, trading below moving averages and experiencing decreased investor participation.

As of 02-Sep, Cell Point (India) Ltd's stock price is falling, currently at 16.00, reflecting a decrease of 0.25 or 1.54%. This decline is supported by several factors. Over the past week, while the stock has shown a slight increase of 3.23%, it has underperformed against the benchmark Sensex, which fell by 1.21%. However, the stock has a negative performance over the longer term, with a 1-month decline of 7.25% and a year-to-date drop of 3.03%. <BR><BR>Moreover, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Additionally, there has been a notable decrease in investor participation, with delivery volume on September 1 dropping by 58.33% compared to the 5-day average. This lack of interest from investors further contributes to the stock's downward movement. Overall, these factors collectively explain the current decline in Cell Point (India) Ltd's stock price.

Which are the latest news on Cell Point?

What does Cell Point do?

Cell Point (India) Ltd is a micro-cap retail company incorporated in 2013 and converted to a public company in 2022, with no recent sales or profit reported. It has a market cap of INR 30 Cr, a P/E ratio of 508.00, and a debt-equity ratio of 0.96.

Overview: <BR>Cell Point (India) Ltd operates in the retailing industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Cell Point (India) Ltd was incorporated on April 10, 2013, as 'Cell Point (India) Private Limited' and later converted into a public company on November 25, 2022. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 30 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 508.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.96 <BR>Return on Equity: 0.08% <BR>Price-to-Book: 0.41 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Cell Point?

Cell Point's peers include Purv Flexi, Fonebox Retail, Osia Hyper Reta, Kotia Enterprise, TAVEXIA LIFECARE, Umiya Mobile, and MRP Agro. Fonebox Retail shows the best management risk and growth, while Cell Point has below-average growth and a 1-year return of -7.39%.

Peers: The peers of Cell Point are Purv Flexi, Fonebox Retail, Osia Hyper Reta., Kotia Enterprise, TAVEXIA LIFECARE, Umiya Mobile, and MRP Agro.<BR><BR>Quality Snapshot: Below Average management risk is observed at Purv Flexi, Cell Point, Kotia Enterprise, and TAVEXIA LIFECARE, while Average management risk is found at Fonebox Retail and Umiya Mobile, and Good management risk is noted at Osia Hyper Reta. Excellent growth is seen at Fonebox Retail, while Below Average growth is present at Purv Flexi, Cell Point, Kotia Enterprise, TAVEXIA LIFECARE, Umiya Mobile, and MRP Agro, and Average growth is found at Osia Hyper Reta. Capital Structure is rated as Excellent at Fonebox Retail, Good at TAVEXIA LIFECARE and MRP Agro, and Below Average at Purv Flexi, Cell Point, Osia Hyper Reta, Kotia Enterprise, Umiya Mobile.<BR><BR>Return Snapshot: Fonebox Retail has the highest 1-year return at 16.28%, while Osia Hyper Reta. has the lowest at -85.94%, with Cell Point's 1-year return of -7.39% being significantly better than Osia Hyper Reta. Additionally, Osia Hyper Reta. and TAVEXIA LIFECARE have negative six-month returns.

How big is Cell Point?

As of 10th June, Cell Point (India) Ltd has a market capitalization of 28.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for the latest quarterly performance, but as of March 2025, Shareholder's Funds are 74.25 Cr and Total Assets are 137.69 Cr.

As of 10th June, <BR><BR>Market Cap: Cell Point (India) Ltd has a market capitalization of 28.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest quarterly performance, including Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 74.25 Cr and Total Assets valued at 137.69 Cr.

Is Cell Point overvalued or undervalued?

As of November 14, 2025, Cell Point is considered overvalued with a PE ratio of 98.49, significantly higher than its peers, and despite a recent one-week return of 8.33%, it has declined 27.1% year-to-date, indicating it is not a favorable investment at its current price.

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all suggesting that the stock is priced significantly higher than its earnings potential.<BR><BR>In comparison to its peers, Cell Point's valuation appears particularly high when contrasted with PTC India, which has a PE ratio of 7.52 and is rated as very attractive, and Optiemus Infra, rated as fair with a PE of 75.09. This stark difference in valuation metrics underscores the overvaluation of Cell Point. Additionally, while the stock has shown a recent one-week return of 8.33% compared to the Sensex's 1.64%, its year-to-date performance is concerning, with a decline of 27.1% against a 9.58% rise in the Sensex, further reinforcing the notion that Cell Point is not a favorable investment at its current price.

How has been the historical performance of Cell Point?

Cell Point has shown consistent growth in net sales, reaching 324.71 Cr in March 2025, but profitability metrics have fluctuated, with operating profit declining from 19.34 Cr in March 2023 to 8.88 Cr in March 2025. Total assets increased to 137.69 Cr in March 2025, while cash flow improved to 0.00 Cr, indicating ongoing liquidity challenges.

Answer:<BR>The historical performance of Cell Point shows a steady increase in net sales over the years, reaching 324.71 Cr in March 2025, up from 321.23 Cr in March 2024, and significantly higher than 295.67 Cr in March 2023. The total operating income mirrored this trend, with a rise to 324.71 Cr in March 2025 from 321.23 Cr in the previous year. However, the operating profit (PBDIT) has seen fluctuations, peaking at 19.34 Cr in March 2023 before declining to 8.88 Cr in March 2025. Profit before tax also experienced a decline, with 2.81 Cr reported in March 2025 compared to 9.87 Cr in March 2023. Profit after tax followed a similar pattern, increasing to 2.26 Cr in March 2025 from 1.69 Cr in March 2024 but down from 6.73 Cr in March 2023. <BR><BR>In terms of assets and liabilities, total assets grew to 137.69 Cr in March 2025 from 133.10 Cr in March 2024, with total liabilities also increasing to 137.69 Cr from 133.10 Cr. The company's cash flow from operating activities was notably negative in March 2024 at -7.00 Cr, but improved to 0.00 Cr in March 2025. The net cash outflow for March 2025 was -5.00 Cr, a decline from a net inflow of 1.00 Cr in March 2024. Overall, while Cell Point has shown growth in sales and total assets, profitability metrics have fluctuated, indicating challenges in maintaining profit levels in recent periods. <BR><BR>Breakdown:<BR>Cell Point's net sales have consistently increased, reaching 324.71 Cr in March 2025, up from 321.23 Cr in March 2024, and significantly higher than previous years. The total operating income followed suit, reflecting the same growth trajectory. However, operating profit (PBDIT) peaked at 19.34 Cr in March 2023 and has since declined to 8.88 Cr in March 2025, indicating volatility in profitability. Profit before tax also decreased to 2.81 Cr in March 2025 from a higher 9.87 Cr in March 2023, while profit after tax showed a slight increase to 2.26 Cr in March 2025 from 1.69 Cr in the prior year, but was down from 6.73 Cr in March 2023. On the balance sheet, total assets rose to 137.69 Cr in March 2025, with total liabilities matching this figure, reflecting a stable financial position despite the challenges in profitability. Cash flow from operating activities improved to 0.00 Cr in March 2025 after a negative performance in the previous year, though the net cash outflow indicates ongoing liquidity challenges.

Who are the top shareholders of the Cell Point?

The top shareholder of Cell Point is Mohan Prasad Panday, who holds 64.54% of the shares. Individual investors own 24.39%, with no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Cell Point are primarily the promoters, with Mohan Prasad Panday holding the largest share at 64.54%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Individual investors collectively hold 24.39% of the shares.

What is the technical trend for Cell Point?

As of May 12, 2025, Cell Point's trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite a mildly bullish indication from the weekly MACD and KST.

As of 12 May 2025, the technical trend for Cell Point has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages reflect a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and the RSI shows no signal in both time frames. The KST and Dow Theory are mildly bullish on the weekly and monthly charts, providing some support to the overall outlook. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and Bollinger Bands.

When is the next results date for Cell Point?

No Upcoming Board Meetings

Has Cell Point declared dividend?

Yes, Cell Point (India) Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 19, 2024. However, the company has experienced significant price declines, resulting in negative total returns over various periods.

Cell Point (India) Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 19 Sep 2024<BR><BR>Dividend Yield: 1.07%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -34.26%, the dividend return was 0%, resulting in a total return of -34.26%.<BR><BR>For the 1-year period, the price return was -46.31%, the dividend return was 0.56%, leading to a total return of -45.75%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there were no changes in price or dividends, leading to a total return of 0.0%.<BR><BR>In the 5-year period, there was again no price or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Cell Point has declared a dividend, the total returns over various periods indicate significant losses in the short term, with no returns from dividends in most periods. The company appears to be struggling, as reflected in the negative price returns.